ID   MAVS_RAT                Reviewed;         507 AA.
AC   Q66HG9;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   24-JUL-2024, entry version 151.
DE   RecName: Full=Mitochondrial antiviral-signaling protein;
DE            Short=MAVS;
DE   AltName: Full=Interferon beta promoter stimulator protein 1;
DE            Short=IPS-1;
DE   AltName: Full=Virus-induced-signaling adapter;
DE            Short=VISA;
GN   Name=Mavs; Synonyms=Ips1, Visa;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Adapter required for innate immune defense against viruses.
CC       Acts downstream of DHX33, RIGI and IFIH1/MDA5, which detect
CC       intracellular dsRNA produced during viral replication, to coordinate
CC       pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to
CC       the subsequent induction of antiviral cytokines such as IFN-beta and
CC       RANTES (CCL5). Peroxisomal and mitochondrial MAVS act sequentially to
CC       create an antiviral cellular state. Upon viral infection, peroxisomal
CC       MAVS induces the rapid interferon-independent expression of defense
CC       factors that provide short-term protection, whereas mitochondrial MAVS
CC       activates an interferon-dependent signaling pathway with delayed
CC       kinetics, which amplifies and stabilizes the antiviral response. May
CC       activate the same pathways following detection of extracellular dsRNA
CC       by TLR3. May protect cells from apoptosis. Involved in NLRP3
CC       inflammasome activation by mediating NLRP3 recruitment to mitochondria.
CC       {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- SUBUNIT: Self-associates and polymerizes (via CARD domains) to form 400
CC       nM long three-stranded helical filaments on mitochondria, filament
CC       nucleation requires interaction with RIGI whose CARD domains act as a
CC       template for filament assembly. Interacts with RIGI, IFIH1/MDA5, TRAF2,
CC       TRAF6 and C1QBP. May interact with FADD, RIPK1, CHUK and IKBKB.
CC       Interacts (when phosphorylated) with IRF3; following activation and
CC       phosphorylation on the pLxIS motif by TBK1, recruits IRF3. Interacts
CC       with NLRX1. Interaction with NLRX1 requires the CARD domain. Interacts
CC       with PSMA7 (By similarity). Interacts with TRAFD1 (By similarity).
CC       Interacts (via C-terminus) with PCBP2 in a complex containing
CC       MAVS/IPS1, PCBP2 and ITCH. Interacts with CYLD. Interacts with SRC.
CC       Interacts with DHX58/LGP2 and IKBKE. Interacts with STING1. Interacts
CC       with IFIT3 (via N-terminus). Interacts with TBK1 only in the presence
CC       of IFIT3. Interacts with TTLL12; the interaction prevents MAVS binding
CC       to TBK1 and IKBKE (By similarity). Interacts with MUL1. Interacts with
CC       ANKRD17. Interacts with NDFIP1. Interacts with SMURF1; the interaction
CC       is mediated by NDFIP1 and leads to MAVS ubiquitination and degradation.
CC       Interacts with UBXN1; this interaction inhibits MAVS-mediated antiviral
CC       pathway. Interacts (via C-terminus) with GPATCH3; the interaction is
CC       markedly increased upon viral infection. Directly interacts (via CARD
CC       domain) with ATG5 and ATG12, either as ATG5 and ATG12 monomers or as
CC       ATG12-ATG5 conjugates (By similarity). Interacts with DHX33 (via the
CC       helicase C-terminal domain) (By similarity). Interacts with DDX3X (via
CC       C-terminus); this interaction may occur rapidly, but transiently after
CC       viral infection (By similarity). The interaction with DDX3X potentiates
CC       MAVS-mediated IFNB induction (By similarity). Conversely inhibition of
CC       this interaction prevents MAVS-mediated IFNB induction (By similarity).
CC       Transiently interacts with TRAF3 early during viral infection (By
CC       similarity). Interacts with CLPB (By similarity). Interacts with
CC       TRAF3IP3 (By similarity). Interacts with TOMM70; the interaction is
CC       enhanced by virus infection (By similarity). Interacts with ZNFX1 (By
CC       similarity). Interacts with DHX15 (By similarity). Interacts with
CC       N4BP3; this interaction promotes the polyubiquitination of MAVS (By
CC       similarity). Interacts with TAX1BP1; this interaction induces MAVS
CC       polyubiquitination (By similarity). Interacts with NLRP3; promoting
CC       NLRP3 recruitment to mitochondria and activation of the NLRP3
CC       inflammasome (By similarity). Interacts with ECSIT; this interaction
CC       bridges RIGI to the MAVS complex at the mitochondrion (By similarity).
CC       Interacts with UBL7; this interaction promotes MAVS 'Lys-27'-linked
CC       ubiquitination leading to type I interferon production (By similarity).
CC       Interacts (via transmembrane domain) with SMIM30/MAVI1 (via
CC       transmembrane domain); the interaction disrupts MAVS interaction with
CC       RIGI and inhibits MAVS aggregation, resulting in the repression of type
CC       I interferon signaling and innate immune responses (By similarity).
CC       {ECO:0000250|UniProtKB:Q7Z434, ECO:0000250|UniProtKB:Q8VCF0}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane
CC       {ECO:0000250|UniProtKB:Q7Z434}; Single-pass membrane protein
CC       {ECO:0000250|UniProtKB:Q7Z434}. Mitochondrion
CC       {ECO:0000250|UniProtKB:Q7Z434}. Peroxisome
CC       {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- DOMAIN: Both CARD and transmembrane domains are essential for antiviral
CC       function. The CARD domain is responsible for interaction with RIGI and
CC       IFIH1/MDA5 (By similarity). {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- DOMAIN: The transmembrane domain and residues 288-424 are essential for
CC       its interaction with DHX58/LGP2. {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- DOMAIN: The pLxIS motif constitutes an IRF3-binding motif: following
CC       phosphorylation by TBK1, the phosphorylated pLxIS motif of MAVS
CC       recruits IRF3. IRF3 is then phosphorylated and activated by TBK1 to
CC       induce type-I interferons and other cytokines.
CC       {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- PTM: Following activation, phosphorylated by TBK1 at Ser-422 in the
CC       pLxIS motif. The phosphorylated pLxIS motif constitutes an IRF3-binding
CC       motif, leading to recruitment of the transcription factor IRF3 to
CC       induce type-I interferons and other cytokines.
CC       {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- PTM: Ubiquitinated. Undergoes 'Lys-48'-linked polyubiquitination
CC       catalyzed by ITCH; ITCH-dependent polyubiquitination is mediated by the
CC       interaction with PCBP2 and leads to MAVS/IPS1 proteasomal degradation.
CC       Ubiquitinated by RNF125, leading to its degradation by the proteasome.
CC       Undergoes 'Lys-48'-linked ubiquitination catalyzed by SMURF1.
CC       Ubiquitinated via 'Lys-63'-linked ubiquitination at Lys-10 by TRIM31,
CC       promoting MAVS polymerization and formation of three-stranded helical
CC       filaments on mitochondria. Undergoes 'Lys-63'-linked ubiquitination
CC       leading to enhanced interaction between MAVS and TRAF2. Undergoes 'Lys-
CC       27'-linked ubiquitination by UBE2N and TRIM21 leading to enhanced
CC       interaction between MAVS and TBK1 (By similarity). Deubiquitinated by
CC       USP10 leading to attenuation of RIGI-mediated MAVS aggregation and
CC       production of type I interferon (By similarity). Undergoes 'Lys-48'-
CC       linked polyubiquitination catalyzed by RNF115 leading to its
CC       degradation (By similarity). {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- PTM: Proteolytically cleaved by apoptotic caspases during apoptosis,
CC       leading to its inactivation. Cleavage by CASP3 during virus-induced
CC       apoptosis inactivates it, preventing cytokine overproduction.
CC       {ECO:0000250|UniProtKB:Q7Z434}.
CC   -!- PTM: Palmitoylated by ZHDDC4. Palmitoylation promotes MAVS
CC       stabilization and activation by inhibiting 'Lys-48'- but facilitating
CC       'Lys-63'-linked ubiquitination. {ECO:0000250|UniProtKB:Q7Z434}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC081869; AAH81869.1; -; mRNA.
DR   RefSeq; NP_001005556.1; NM_001005556.1.
DR   RefSeq; XP_006235096.1; XM_006235034.3.
DR   RefSeq; XP_006235097.1; XM_006235035.3.
DR   RefSeq; XP_006235098.1; XM_006235036.2.
DR   RefSeq; XP_008760401.1; XM_008762179.2.
DR   AlphaFoldDB; Q66HG9; -.
DR   SMR; Q66HG9; -.
DR   IntAct; Q66HG9; 1.
DR   MINT; Q66HG9; -.
DR   STRING; 10116.ENSRNOP00000033476; -.
DR   GlyGen; Q66HG9; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q66HG9; -.
DR   PhosphoSitePlus; Q66HG9; -.
DR   jPOST; Q66HG9; -.
DR   PaxDb; 10116-ENSRNOP00000033476; -.
DR   Ensembl; ENSRNOT00000090764.2; ENSRNOP00000073053.1; ENSRNOG00000025295.5.
DR   Ensembl; ENSRNOT00055008896; ENSRNOP00055006764; ENSRNOG00055005539.
DR   Ensembl; ENSRNOT00060004295; ENSRNOP00060003008; ENSRNOG00060002683.
DR   Ensembl; ENSRNOT00065022557; ENSRNOP00065017500; ENSRNOG00065013707.
DR   GeneID; 311430; -.
DR   KEGG; rno:311430; -.
DR   UCSC; RGD:1359371; rat.
DR   AGR; RGD:1359371; -.
DR   CTD; 57506; -.
DR   RGD; 1359371; Mavs.
DR   eggNOG; ENOG502SAUA; Eukaryota.
DR   GeneTree; ENSGT00510000049120; -.
DR   InParanoid; Q66HG9; -.
DR   OMA; PHIDQKF; -.
DR   OrthoDB; 5358122at2759; -.
DR   PhylomeDB; Q66HG9; -.
DR   TreeFam; TF333444; -.
DR   Reactome; R-RNO-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-RNO-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   Reactome; R-RNO-9833482; PKR-mediated signaling.
DR   PRO; PR:Q66HG9; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000025295; Expressed in heart and 19 other cell types or tissues.
DR   GO; GO:0031966; C:mitochondrial membrane; ISO:RGD.
DR   GO; GO:0005741; C:mitochondrial outer membrane; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; ISO:RGD.
DR   GO; GO:0005777; C:peroxisome; ISO:RGD.
DR   GO; GO:0050700; F:CARD domain binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0060090; F:molecular adaptor activity; ISO:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0039552; F:RIG-I binding; ISO:RGD.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:RGD.
DR   GO; GO:0002218; P:activation of innate immune response; ISS:UniProtKB.
DR   GO; GO:0140374; P:antiviral innate immune response; ISO:RGD.
DR   GO; GO:0071360; P:cellular response to exogenous dsRNA; ISS:UniProtKB.
DR   GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; ISO:RGD.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; ISS:UniProtKB.
DR   GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; ISO:RGD.
DR   GO; GO:0071651; P:positive regulation of chemokine (C-C motif) ligand 5 production; ISO:RGD.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; ISS:UniProtKB.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; ISS:UniProtKB.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISS:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISS:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISO:RGD.
DR   GO; GO:0071660; P:positive regulation of IP-10 production; ISO:RGD.
DR   GO; GO:0002735; P:positive regulation of myeloid dendritic cell cytokine production; ISS:UniProtKB.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISO:RGD.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISO:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0060760; P:positive regulation of response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; ISO:RGD.
DR   GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0070585; P:protein localization to mitochondrion; ISO:RGD.
DR   GO; GO:1900063; P:regulation of peroxisome organization; ISO:RGD.
DR   GO; GO:0039529; P:RIG-I signaling pathway; ISO:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   CDD; cd08811; CARD_IPS1; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   InterPro; IPR031964; CARD_dom.
DR   InterPro; IPR042144; CARD_IPS1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR052787; MAVS.
DR   PANTHER; PTHR21446; DUF3504 DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR21446:SF6; MITOCHONDRIAL ANTIVIRAL-SIGNALING PROTEIN; 1.
DR   Pfam; PF16739; CARD_2; 1.
PE   1: Evidence at protein level;
KW   Antiviral defense; Host-virus interaction; Immunity; Innate immunity;
KW   Isopeptide bond; Lipoprotein; Membrane; Methylation; Mitochondrion;
KW   Mitochondrion outer membrane; Palmitate; Peroxisome; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..507
FT                   /note="Mitochondrial antiviral-signaling protein"
FT                   /id="PRO_0000144098"
FT   TOPO_DOM        1..482
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        483..500
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        501..507
FT                   /note="Mitochondrial intermembrane"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          10..77
FT                   /note="CARD"
FT   REGION          10..77
FT                   /note="Required for interaction with NLRX1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   REGION          123..238
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          143..147
FT                   /note="Interaction with TRAF2"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   REGION          153..158
FT                   /note="Interaction with TRAF6"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   REGION          250..326
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          340..507
FT                   /note="Interaction with DHX33"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VCF0"
FT   REGION          350..401
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          423..474
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..440
FT                   /note="Interaction with TRAF6"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOTIF           419..422
FT                   /note="pLxIS motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   COMPBIAS        277..326
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        350..394
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        459..473
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            408..409
FT                   /note="Cleavage; by CASP3"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOD_RES         152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         157
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOD_RES         172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VCF0"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOD_RES         186
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOD_RES         220
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOD_RES         234
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VCF0"
FT   MOD_RES         256
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   MOD_RES         387
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VCF0"
FT   MOD_RES         422
FT                   /note="Phosphoserine; by TBK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   LIPID           79
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   CROSSLNK        10
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
FT   CROSSLNK        305
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q7Z434"
SQ   SEQUENCE   507 AA;  53805 MW;  D2924B1E34CADE47 CRC64;
     MTFAEEKTYK YIRYNHSKFC CVDVLEILPY LSCLTTSDQD RLRASYKQLG NQGTLWELFN
     TLQRRPGWVE VFIRALRICE LPGLAEQVTR VYQSYLPPGA SLHSLDPLQS PRIPTTVSEP
     SAFAAGHTIP DSGFQDKPGY PKPVQDTQPP KSPVENSEEP PQANFGAIPR MSGDSLISSP
     NPPALSPQPS REHPEQEPEL GGPSTANVDS VPIATYGPVS PTVSFQPLPR IAPRTNLSPG
     VTVSALSAKT TLSSSSTGSA FAKGAGDQAK AATCVSTKEG VPTNSVTTSS VPSIKPVPVN
     TMSSKLPIST KSTAATPSTV PTNIAPSKLP INSVYTGIVP SKVTASVAKA SASTMPPERN
     NKQAKETLEA PATVVTTGSS LTRPDISSRS LHSGPELSKP GVLVSQVDNE PFSACSMDLA
     ISPSTSLGSE PNHGPEENEY SSFRIQVDKS PSVDLLGSPE PLATQQSPEE EEPCASSVSW
     AKWLGATSAL LAAFLAVMLY RSRHLAQ
//
